Sarepta Therapeutics (SRPT) Posts Smaller Q1 Loss

Sarepta Therapeutics (NASDAQ: SRPT) reported Q1 EPS of ($0.56), $0.71 better than the analyst estimate of ($1.27). Revenue for the quarter came in at $188.8 million versus the consensus estimate of $206.44 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• Trump discloses over $1.4 billion in crypto income in 2025 filing
• General Mills (GIS) Tops Q4 EPS by 14c, Beats on Revenue; Offers FY27 EPS Guidance
• Snail, Inc. sets 1-for-5 reverse stock split to meet Nasdaq rules